digestive
Advances in the Use of Milk Thistle (Silybum marianum).
Submitted by Site Editor on Mon, 2007-06-11 05:32.Advances in the Use of Milk Thistle (Silybum marianum).: Integr Cancer Ther. 2007 Jun;6(2):104-9 Authors: Post-White J, Ladas EJ, Kelly KM
Milk thistle (Silybum marianum) is an herbal supplement used to treat liver and biliary disorders. Silymarin, a mixture of flavanoid complexes, is the active component that protects liver and kidney cells from toxic effects of drugs, including chemotherapy. Although milk thistle has not significantly altered the course of chronic liver disease, it has reduced liver enzyme levels and demonstrated anti-inflammatory and T cell-modulating effects. There is strong preclinical evidence for silymarin's hepatoprotective and anticarcinogenic effects, including inhibition of cancer cell growth in human prostate, skin, breast, and cervical cells. Milk thistle is considered safe and well-tolerated, with gastrointestinal upset, a mild laxative effect, and rare allergic reaction being the only adverse events reported when taken within the recommended dose range. More clinical trials of rigorous methodology, using standardized and well-defined products and dosages, are needed to evaluate the potential of silymarin against liver toxicity, chronic liver disease, and human cancers.
Efficacy and tolerability of potato juice in dyspeptic patients: A pilot study.
Submitted by Site Editor on Fri, 2006-06-09 03:53.Efficacy and tolerability of potato juice in dyspeptic patients: A pilot study.: Phytomedicine. 2006 Jan; 13(1-2): 11-5 Chrubasik S, Chrubasik C, Torda T, Madisch A
In Europe, use of potatoes (Solani tuberosi tuberecens) is a traditional remedy for stomach complaints. We performed a pilot study on the effectiveness and tolerability of freshly squeezed potato juice in patients suffering from dyspeptic symptoms. After informed written consent, 44 patients with various dyspeptic symptoms were enrolled, to drink for 1 week twice daily 100ml or more of potato juice (Biotta((R))), if complaints persisted, a further 100ml was recommended. Validated outcome measures included the gastrointestinal symptom (GIS) profile, a disease-specific health assessment questionnaire (QOLRAD) and self-rated treatment success (efficacy, a 5-point Likert Scale). The study was completed by 42 patients. The GIS and QOLRAD scores improved significantly by 41.9+/-40.8% (p=0.001) and 50.7+/-36.1% (p<0.001), respectively (ITT); the absolute values changed from 11.5+/-5.1 to 6.3+/-5.3 (GIS) and 62.0+/-25.7 to 32.0+/-28.8 (QORAD). Sixteen, 18 and 26 patients, respectively, rated the effectiveness of the treatment as very good or good on the GIS, QOLRAD (improvements >60%) and on efficacy, respectively. Poor treatment success was achieved in 13 (GIS), 11 (QOLRAD) and 10 (Efficacy), not necessarily by the same patients. Since about two-thirds of the patients benefited to some extent from the treatment, potato juice in its present formulation may be useful for self-treatment. However, placebo-controlled studies with a longer treatment period are needed to confirm this.
Functional dyspepsia pathogenesis and therapeutic options--implications for management.
Submitted by Site Editor on Fri, 2006-06-09 03:41.Functional dyspepsia pathogenesis and therapeutic options--implications for management.: Dig Liver Dis. 2005 Aug;37(8):547-58 Authors: Smith ML
Functional dyspepsia is far more common than dyspepsia due to organic disease, both in the community and general practice. Proposed aetiopathogenic factors include gastric acid, Helicobacter pylori infection, delayed emptying, hypersensitivity or impaired accommodation of the stomach, dysfunction of the duodenum or brain-gut axis, psychosocial morbidity and post-infective mucosal damage. More effective therapy will depend on the development of drugs targeted at these putative pathophysiological mechanisms. On current evidence tricyclic antidepressants appear to be more effective than either acid suppressants or H. pylori eradication.
Human Endogenous Microbial Ecosystems: The Next Frontier
Submitted by Site Editor on Fri, 2006-06-09 03:24.
Human Endogenous Microbial Ecosystems: The Next Frontier
Presented by: David A. Relman, M.D., Stanford University
Aired date: 10/27/2005 3:21:00 PM Eastern Time
